References
- Tchernev G, Oliveira N, Kandathil LJ et al. 4th National Congress of the Bulgarian Society for Dermatologic Surgery, Sofia, 12th March 2022 with main topics: one step melanoma surgery and drug induced melanoma. Dermatol Reports. 2022 Nov 23;14(4):9542.
- Kordeva S, Cardoso JC, Tchernev G. Congress report of the 5th national congress of the Bulgarian society for dermatologic surgery, Sofia, 11th march 2023 with main topics: nitrosamines as most powerful trigger for skin cancer development and progression/personalised one step melanoma surgery as possible skin cancer treatment option. Georgian Med News. 2023;(337):89-95.
- Nishie K, Norred WP, Wasserman A, et al. Phototoxicity and differential hepatotoxicity as biological indicators of nitrosamine activity. Toxicol Appl Pharmacol. 1972;23:680-691.
- Tchernev G, Broshtilova V. (NDMA) Metformin and (NTTP) sitagliptin induced cutaneous melanomas: links to nitrosogenesis, nitroso-photocarcinogenesis, oncopharmacogenesis and the metabolic reprogramming. Georgian Med News. 2024;(348):132-143.
- Tchernev G, Broshtilova V, Kordeva S. Innovations in dermatologic surgery and melanoma pathogenesis: from the personalized surgery to the concept of genomic mapping/targeting via nitrosamines in drugs: spotlight on contamination of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Georgian Med News. 2025;(358):40-46.
- Tchernev G, Kordeva S, Kirilova H, et al. Polypharmacy and cancer: a new vision for skin cancer pathogenesis-phototoxicity and photocarcinogenicity due to nitrosamine contamination during telmisartan/tamsulosin intake. Georgian Med News. 2024;(356):89-93.
- Research C for DEA. FDA updates and press announcements on Angiotensin II Receptor Blocker (ARB) recalls (Valsartan, Losartan, and Irbesartan) [Internet]. U.S. Food And Drug Administration. 2023. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan
- Research C for DEA. CDER Nitrosamine impurity Acceptable intake Limits [Internet]. U.S. Food And Drug Administration. 2025. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits
- Mercader MF, Voice KA, Trap H, Goetheer VLE. Nitrosamine degradation by UV light in post-combustion CO2 capture: Effect of solvent matrix. Energy Procedia, 2013, 37: 701-716.
- Arimoto-Kobayashi S, Sano K, Machida M, et al. UVA activation of N-dialkylnitrosamines releasing nitric oxide, producing strand breaks as well as oxidative damages in DNA, and inducing mutations in the Ames test. Mutat Res. 2010;691(1-2):47-54.
- Mochizuki H, Nagazawa Y, Arimoto-Kobayashi S. Genotoxicity and the stability of N-nitrosomorpholine activity following UVA irradiation. Mutat Res Genet Toxicol Environ Mutagen. 2024;893:503721
- Schmidtsdorff S, Neumann J, Schmidt AH, et al. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome? Arch Pharm (Weinheim). 2023;356:e2200484.
- Mehlan J, Ueberschaar J, Hagenström K, et al. The use of HCT and/or ACE inhibitors significantly increases the risk of non-melanotic skin cancer in the periocular region. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2745-2751.
- Azoulay L, St-Jean A, Dahl M, et al. Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multisite population-based cohort study. J Am Acad Dermatol. 2023;89(2):243-253.
- Hou A, Li Y, Shadyab AH, et al. Photosensitizing antihypertensive medication and risk of skin cancer among postmenopausal women. J Dtsch Dermatol Ges. 2024;22(2):186-194.
- Davis AE, Kennelley GE, Amaye-Obu T, et al. The phenomenon of phototoxicity and long-term risks of commonly prescribed and structurally diverse drugs. J Photochem Photobiol. 2024;19:100221.
- Tchernev G, Temelkova I. Valsartan Induced Melanoma?! First Description in Medical Literature! Open Access Maced J Med Sci. 2018;6(12):2378-2380.
- Tchernev G, Temelkova I. Drug-Induced Melanoma: Irbesartan Induced Cutaneous Melanoma! First Description in the World Literature! Open Access Maced J Med Sci. 2019;7(1):114-116.
- Tchernev G, Temelkova I. Valsartan/hydrochlorothiazide induced prostate carcinoma in a patient who subsequently developed melanoma. J Biol Regul Homeost Agents. 2019;33(4):1125-1127.
- Tchernev G, Patterson JW. Telmisartan/hydrochlorothiazide-induced nevus-associated cutaneous melanoma: first report in the medical literature. Expert Rev Clin Pharmacol. 2021;14(3):289-293.
- Mansouri I, Botton J, Semenzato L, et al. N-nitrosodimethylamine-Contaminated Valsartan and Risk of Cancer: A Nationwide Study of 1.4 Million Valsartan Users. J Am Heart Assoc. 2022;11(24):e8067.
- IARC Monographs evaluation of the carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus [Internet]. Available from: https://www.iarc.who.int/news-events/iarc-monographs-evaluation-of-the-carcinogenicity-of-hydrochlo-rothiazide-voriconazole-and-tacrolimus/
- Cogliano VJ, Corsini E, Fournier A, et al. Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus. Lancet Oncol. 2025;26(1):15-16.
- Nardone B, Majewski S, Kim AS, et al. Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study. Drug Saf. Tchernev G. A Flavour of death: perindopril induced thick melanoma and bcc of the back. potential role of the generic substance or/-and possible nitrosamine contamination as skin cancer key triggering factors. Georgian Med News. 2023;(336):123-125.
- Tchernev G. A Flavour of death: perindopril induced thick melanoma and bcc of the back. potential role of the generic substance or/-and possible nitrosamine contamination as skin cancer key triggering factors. Georgian Med News. 2023 Mar;(336):123-125.
- Tchernev G. Nitrosogenesis of cutaneous melanoma: simultaneously development of primary cutaneous thick melanoma of the breast, thin melanoma/dysplastic mole of the back during parallel intake of bisoprolol, amlodipine and valsartan/hct: nitrosamine polycontamination in the multimedication as the most powerful skin cancer trigger. Georgian Med News. 2023;(339):83-88.
- Tchernev G, Ivanov L, Kordeva S, et al. Academic criticism: Antihypertensives, Nitrosamines and melanoma-Beyond the Medical Aspects of the Socially Significant Human problem. Current state and future directions. Clin Res Dermatol Open Access 2024;11(2): 1-14.
- Tchernev G, Poterov G. Simultaneously development of Cutaneous melanoma, Colon carcinoma and Kaposi Sarcoma under Valsartan/Hudrochlorothiazide. Clin Res Dermatol Open Access 2020; 7(5): 1-8.
- Lolla S, Ajay R, Saba S, et al. The Risk of Cancer correlated with Nitrosamine Exposure. JCHR 2024; 14(1): 1105-1110.
- Sipahi I. Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials. PLoS One. 2022;17(3):e0263461.
- Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627-36.